Assembly Biosciences Inc (NASDAQ:ASMB) shares reached a new 52-week low during trading on Monday . The company traded as low as $13.13 and last traded at $14.80, with a volume of 81780 shares trading hands. The stock had previously closed at $18.79.

A number of research analysts recently commented on ASMB shares. BidaskClub raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Thursday, February 21st. Finally, Chardan Capital reissued a “hold” rating and issued a $30.00 target price on shares of Assembly Biosciences in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $43.00.

The company has a market cap of $500.77 million, a PE ratio of -3.71 and a beta of 1.75.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($1.03) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.91) by ($0.12). Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. The company had revenue of $3.74 million for the quarter, compared to the consensus estimate of $3.69 million. On average, equities analysts expect that Assembly Biosciences Inc will post -4.61 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in ASMB. Wells Fargo & Company MN grew its stake in shares of Assembly Biosciences by 18.3% during the third quarter. Wells Fargo & Company MN now owns 64,444 shares of the biopharmaceutical company’s stock valued at $2,394,000 after buying an additional 9,977 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Assembly Biosciences by 3.8% during the third quarter. JPMorgan Chase & Co. now owns 82,769 shares of the biopharmaceutical company’s stock valued at $3,074,000 after buying an additional 3,022 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Assembly Biosciences by 17.4% during the third quarter. Bank of New York Mellon Corp now owns 80,233 shares of the biopharmaceutical company’s stock valued at $2,979,000 after buying an additional 11,902 shares during the last quarter. BlackRock Inc. grew its stake in shares of Assembly Biosciences by 48.8% during the third quarter. BlackRock Inc. now owns 1,845,956 shares of the biopharmaceutical company’s stock valued at $68,557,000 after buying an additional 605,204 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Assembly Biosciences by 131.4% during the third quarter. FMR LLC now owns 187,700 shares of the biopharmaceutical company’s stock valued at $6,971,000 after buying an additional 106,600 shares during the last quarter. 83.62% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2019/04/15/assembly-biosciences-asmb-hits-new-52-week-low-at-13-13.html.

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Further Reading: What is Cost of Goods Sold (COGS)?

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.